drugset / Trial / NCT05707754

Sphenopalatine Ganglion Block Study

NCT05707754

Phase 1 Completed 220 enrolled Montefiore Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to compare the administration and dosage of bupivacaine for sphenopalatine ganglion (SPG) nerve block. The main question\[s\] it aims to answer are: * Does a high dose (3ml) give more relief than a low dose (1ml)? * Does bilateral administration give more relief than unilateral? Participants with headaches will be asked to lie down and have SPG block performed. Researchers will compare dosage and administration to see how symptoms are reduced.

Timeline

Start
2023-03-06
Primary completion
2024-08-30
Completion
2024-08-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 1 ml Topical
Comparator Bupivacaine Other / unclassified 3 ml Topical

Indications

No indication recorded.